News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
SINO BIOPHARM To Present Research Results of 2 Innovative Drugs at ERS in Sep
SINO BIOPHARM (01177.HK) announced that the research results of two innovative drugs developed by the Group, “TQC3721 (PDE3/4 inhibitor)” and “TQC2731 (TSLP monoc...
Reset
Send
The window will close in 5 seconds
SINO BIOPHARM To Present Research Results of 2 Innovative Drugs at ERS in Sep
Close
Recommend
16
Positive
25
Negative
5
 
SHORT SELL
 
STOCK INFO

SINO BIOPHARM (01177.HK)  +0.060 (+1.609%)    Short selling $56.68M; Ratio 9.537%   announced that the research results of two innovative drugs developed by the Group, “TQC3721 (PDE3/4 inhibitor)” and “TQC2731 (TSLP monoclonal antibody)”, will be presented at the 2024 annual meeting of European Respiratory Society (ERS 2024) to be held on 7-11 September.

TQC3721 is an inhaled PDE3/4 inhibitor intended for the maintenance therapy of chronic obstructive pulmonary disease (COPD) and is the second fastest developing drug in the world amongst innovative drugs with the same target. Currently, TQC3721 has completed phase I and phase IIa clinical trials, and its research data will be published at ERS 2024 in the form of poster, one of which is the Late Breaking Abstract.

TQC2731 is a TSLP monoclonal antibody, currently undergoing phase II clinical trial in patients with asthma and chronic sinusitis with nasal polyps, and its development progress is among the fastest in the world. The phase I study data will be published in the form of a poster at ERS 2024.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2024-10-10 16:25.)

AAStocks Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.